6,742 Shares in Insulet Co. (NASDAQ:PODD) Bought by Avanza Fonder AB

Avanza Fonder AB bought a new position in shares of Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,742 shares of the medical instruments supplier’s stock, valued at approximately $1,760,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Baillie Gifford & Co. raised its position in shares of Insulet by 20.7% during the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after acquiring an additional 389,639 shares during the last quarter. Geode Capital Management LLC raised its holdings in Insulet by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after purchasing an additional 22,850 shares during the last quarter. Clearbridge Investments LLC lifted its position in shares of Insulet by 6.0% in the 2nd quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after purchasing an additional 75,526 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after purchasing an additional 163,388 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PODD. Canaccord Genuity Group upped their price target on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Raymond James upped their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. BTIG Research lifted their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. TD Cowen increased their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, Citigroup boosted their target price on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $272.81.

Insulet Stock Up 1.1 %

PODD opened at $275.81 on Friday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company’s 50-day moving average is $266.30 and its 200 day moving average is $232.70. The firm has a market capitalization of $19.35 billion, a P/E ratio of 47.23, a PEG ratio of 3.41 and a beta of 1.22.

Insiders Place Their Bets

In other news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.